Work

Synergy of imaging modalities and omics profiling: Unlocking unmet clinical potentials of novel radiopharmaceuticals

Year: 2026
Type: article
Abstract: Nuclear medicine is entering a period of substantial change, shaped by advances in multimodal imaging, multi-omics profiling, and artificial intelligence (AI)-based analytics.Radiopharmaceuticals directed at defined molecular targets, including prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAP), and somatostatin receptors, have shown considerable diagnostic and therapeutic value.1,2 Yet their clinical impact remains constrained by patient-to-patient variability in response, by the complexity of tumor microenvironments that shapes radiopharmaceutical uptake, retention, and efficacy, and by the limited use of molecular profiling in day-to-day clinical workflows.Cancer treatment more broadly has evolved substantially over recent decades, moving from largely cytotoxic approaches toward increasingly targeted, biomarker-guided strategies. 3Combining multimodal imaging with comprehensive omics profiling offers one route toward more individualized nuclear medicine, supporting patient stratification, treatment optimization, and longitudinal response monitoring grounded in molecular and phenotypic data.4,5 Multimodal molecular imaging, particularly hybrid positron emission tomography/computed tomography (PET/CT) and PET/ magnetic resonance imaging (MRI), has improved our capacity to characterize tumor heterogeneity with high spatial and temporal resolution.Combining the functional sensitivity of PET with the anatomical detail of CT, or the soft-tissue contrast of MRI, allows disease burden, metabolic activity, and morphological change to be assessed within a single imaging session.6 Total-body PET technology has extended this further, enabling simultaneous tracer-kinetic measurement across tissues and organs and offering a more detailed view of systemic disease processes, pharmacokinetic modeling, and individualized radiopharmaceutical biodistribution.7 Together, these developments provide the imaging foundation needed to meaningfully incorporate multi-omics data into clinical decision-making and treatment planning.Combining quantitative imaging biomarkers with genomic, transcriptomic, and proteomic data creates opportunities to build predictive models that can inform radiopharmaceutical selection, dosing, and treatment sequencing.Translating this potential into practice, however, requires identifying which omics layers are actually informative for a given radiopharmaceutical decision.To date, transcriptomic and genomic markers of target expression, for example PSMA or somatostatin receptor gene expression, have the clearest established link to radiopharmaceutical selection, while proteomic and metabolomic signatures remain largely at the exploratory research stage.8 Companion diagnostics developed through imaging-omics integration can help identify patients most likely to benefit from a specific radiopharmaceutical therapy, improving outcomes while reducing unnecessary exposure to ineffective treatment.This precision approach is consistent with the broader goals of value-based and personalized healthcare.
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7213645819
FWCI:
Cites: 26
Cited by:
Related to: 10